ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancerDavid Planchard, Dariusz M. Kowalski, Niels Reinmuth et al.|Annals of Oncology|2020Cited by 164
The gefitinib long-term responder (LTR)—A cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)Sandra Gottschling, Roland Penzel, Esther Herpel et al.|Lung Cancer|2012Cited by 13
Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)Frank Griesinger, Dimitri Flieger, Claas Wesseler et al.|JTO Clinical and Research Reports|2023Cited by 4